Inhibikase Therapeutics (IKT) Stock Price, News & Analysis

Company Overview

Inhibikase Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for Parkinson’s disease and other neurodegenerative disorders. The company’s research centers on small-molecule inhibitors of Abelson tyrosine kinase, or c-Abl, a protein it is investigating for its role in neurodegeneration.

Its pipeline has included IKT-148009, an oral c-Abl inhibitor being developed for Parkinson’s disease. Inhibikase is based in Atlanta, Georgia, and conducts research and development in the pharmaceutical biotechnology sector.

Key Stats

• Today's Range: $1.49 to $1.58
• 50-Day Range: $1.44 to $2.52
• 52-Week Range: $1.40 to $2.61
• Volume: 69,203 shs
• Average Volume: 1.05 million shs
• Market Capitalization: $211.11 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.75
• Consensus Rating: Moderate Buy

Inhibikase Therapeutics Stock Analysis - MarketRank™

Inhibikase Therapeutics scored higher than 42% of companies evaluated by MarketBeat, and ranked 660th out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.1 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Inhibikase Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on 3 strong buy ratings, 4 buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

Inhibikase Therapeutics has a consensus price target of $4.75, representing about 217.7% upside from its current price of $1.50.

Amount of Analyst Coverage

Inhibikase Therapeutics has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Inhibikase Therapeutics are expected to decrease in the coming year, from ($0.43) to ($0.44) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Inhibikase Therapeutics is -3.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Inhibikase Therapeutics is -3.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Inhibikase Therapeutics has a P/B Ratio of 1.11. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

14.99% of the float of Inhibikase Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Inhibikase Therapeutics has a short interest ratio ("days to cover") of 28.59, which indicates bearish sentiment.

Change versus previous month

Short interest in Inhibikase Therapeutics has recently decreased by 1.01%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Inhibikase Therapeutics does not currently pay a dividend.

Dividend Growth

Inhibikase Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 0.61

News Sentiment

Inhibikase Therapeutics has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 12 news articles for Inhibikase Therapeutics this week, compared to 2 articles on an average week.

MarketBeat Follows

1 people have added Inhibikase Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Inhibikase Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

7.10% of the stock of Inhibikase Therapeutics is held by insiders.

Percentage Held by Institutions

3.81% of the stock of Inhibikase Therapeutics is held by institutions.

Company Calendar

• Last Earnings: 11/10/2026
• Today: 11/13/2026
• Jefferies Global Healthcare Conference: 11/16/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:IKT
• Previous Symbol: NYSE:IKT
• CIK: 1750149
• Web: inhibikase.com
• Phone: (678) 392-3419
• Fax: N/A
• Employees: 35
• Year Founded: 2008

Price Target and Rating

• Average Price Target for Inhibikase Therapeutics: $4.75
• High Price Target: $8.00
• Low Price Target: $1.50
• Potential Upside/Downside: +215.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.90
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.40)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$48.26 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -40.53%
• Return on Assets: -38.44%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 15.34
• Quick Ratio: 15.82

Sales & Book Value

• Annual Sales: $260 thousand
• Price / Sales: 811.95
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.35 per share
• Price / Book: 1.11

Miscellaneous

• Outstanding Shares: 140,270,000
• Free Float: 129,629,000
• Market Cap: $211.11 million
• Optionable: N/A
• Beta: 0.94